Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner

Cancer Research

Volumn 68, Issue 21, 2008, Pages 9087-9095

  Studebaker, Adam W ^a   Storci, Gianluca ^c,d   Werbeck, Jillian L ^a   Sansone, Pasquale ^c,d   Sasser, A Kate ^a   Tavolari, Simona ^d   Huang, Tim ^b   Chan, Michael W Y ^e   Marini, Frank C ^f   Roso, Thomas J ^a   Bonafé, Massimiliano ^c,d   Hall, Brett M ^a,g  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 6; JAGGED1; NOTCH3 RECEPTOR; STAT3 PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CELL; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CELL ISOLATION; CELL STRAIN MCF 7; CONTROLLED STUDY; EMBRYO; FEMALE; FIBROBLAST; GROWTH INHIBITION; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS CELL; MESENCHYME CELL; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SKIN FIBROBLAST; UPREGULATION; XENOGRAFT;

EID: 55349104462     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0400     Document Type: Article

References (50)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
2. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
3. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003;78:105-18.
4. James JJ, Evans AJ, Pinder SE, et al. Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features. Br J Cancer 2003;89:660-5.
5. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
6. Bugge TH, Lund LR, Kombrinck KK, et al. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998;16:3097-104.
7. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
8. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436:123-7.
9. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 2001;10:1907-13.
10. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000;60:2562-6.
11. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-44.
12. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
13. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-a-positive human breast cancer. FASEB J 2007;21:3763-70.
14. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117:3988-4002.
15. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-20.
16. Yashiro M, Ikeda K, Tendo M, Ishikawa T, Hirakawa K. Effect of organ-specific fibroblasts on proliferation and differentiation of breast cancer cells. Breast Cancer Res Treat 2005;90:307-13.
17. Camps JL, Chang SM, Hsu TC, et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A 1990;87:75-9.
18. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001;61:1320-6.
19. van Roozendaal CE, van Ooijen B, Klijn JG, et al. Stromal influences on breast cancer cell growth. Br J Cancer 1992;65:77-81.
20. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
21. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-40.
22. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 2001;98:12072-7.
23. Yang G, Rosen DG, Zhang Z, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 2006;103:16472-7.
24. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 2001;10:257-69, vii-viiii.
25. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001;294:1708-12.
26. Ghosh S, Spagnoli GC, Martin I, et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 2005;204:522-31.
27. Miralem T, Steinberg R, Price D, Avraham H. VEGF(165) requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells. Oncogene 2001;20:5511-24.
28. Sasser AK, Mundy BL, Smith KM, et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett 2007;254:255-64.
29. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85.
30. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2008;111:419-27.
31. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314.
32. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5.
33. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-6.
34. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994;9:462-7.
35. Ancrile B, Lim KH, Counter CM. Oncogenic Rasinduced secretion of IL6 is required for tumorigenesis. Genes Dev 2007;21:1714-9.
36. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer [review]. Breast Cancer Res Treat 2007;102:129-35.
37. DeMichele A, Martin AM, Mick R, et al. Interleukin-6 -174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003;63:8051-6.
38. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
39. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005;65:2532-6.
40. Selander KS, Li L, Watson L, et al. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 2004;64:6924-33.
41. Kassem M, Khosla S, Spelsberg TC, Riggs BL. Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. J Clin Endocrinol Metab 1996;81:513-8.
42. Chavey C, Bibeau F, Gourgou-Bourgade S, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007;9:R15.
43. Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G. DNA damage signaling and p53-dependent senescence after prolonged β-interferon stimulation. Mol Biol Cell 2006;17:1583-92.
44. 2-induced premature senescence of human foreskin fibroblasts expressing or not telomerase. Exp Gerontol 2004;39:1379-89.
45. Noel A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 1993;68:909-15.
46. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-603.
47. Funayama R, Ishikawa F. Cellular senescence and chromatin structure. Chromosoma 2007;116:431-40.
48. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
49. Minn AJ, Kang Y, Serganova I, et al. Distinct organspecific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
50. Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007;9:R32.